AFT's disclosure lacks candour despite chair's pedigree

AFT's disclosure lacks candour despite chair's pedigree
AFT Pharmaceuticals chair David Flacks has a strong background in regulation and governance.
Jenny Ruth
It's hard to fathom that AFT Pharmaceuticals' management and board only realised late on the company's balance date that it was going to miss its earnings guidance by as much as 50%.Founder and managing director Hartley Atkinson assured BusinessDesk that is what happened.AFT has two distinct revenue streams. Licensing agreements and milestone payments are by nature lumpy, and it's easy to understand that Atkinson and his team may have been expecting deals to be signed by March 31, only to see the timing slip a couple of weeks or...

More Markets

NZ sharemarket gains as Fletcher hands over NZICC
Markets

NZ sharemarket gains as Fletcher hands over NZICC

Market leader Fisher & Paykel Healthcare was up 25c. 

Trade Me parent company appoints Owen Wilson as director
Finance

Trade Me parent company appoints Owen Wilson as director

Wilson was CE of $A30b Australian digital-property company Rea Group Ltd.

Me Today’s $2.2m capital raise ‘exceeds expectations’
Markets

Me Today’s $2.2m capital raise ‘exceeds expectations’

The company’s two largest shareholders chipped in $1.5m.

Being AI’s bold plan: No business, still listed
Markets

Being AI’s bold plan: No business, still listed

From wannabe Google challenger to now selling off its last business to escape debt.